7216-73-1

Basic information

• Product Name: methyl 4-O-beta-D-glucopyranosyl-beta-D-glucopyranoside
• Synonyms: methyl 4-O-beta-D-glucopyranosyl-beta-D-glucopyranoside;methyl beta-cellobioside;Methyl cellobioside;Methyl β-cellobioside;Methyl β-D-cellobioside
• CAS NO: 7216-73-1
• Molecular Formula: C₁₃H₂₄O₁₁
• Molecular Weight: 356.32306
• EINECS: 230-604-1
• Mol File: 7216-73-1.mol
• Article Data: 20

Chemical Properties

• Appearance: /
• CAS DataBase Reference: methyl 4-O-beta-D-glucopyranosyl-beta-D-glucopyranoside(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-O-beta-D-glucopyranosyl-beta-D-glucopyranoside(7216-73-1)
• EPA Substance Registry System: methyl 4-O-beta-D-glucopyranosyl-beta-D-glucopyranoside(7216-73-1)

Safety Data

• Hazardous Substances Data: 7216-73-1(Hazardous Substances Data)

Upstream product

• 2914-23-0 barium methoxide 
• 906330-68-5 methyl-[O²,O³,O⁶-triacetyl-O⁴-(tetra-O-acetyl-β-D-glucopyranosyl)-β-D-mannopyranoside] 
• 67-56-1 methanol 
• 14227-66-8 acetobromocellobiose 
• 709-50-2 methyl beta-D-glucopyranoside 
• 59-56-3 α-D-glucopyranosyl-1-phosphate 
• 69308-57-2 Acetic acid (3R,4S,5R,6R)-3-acetoxy-6-acetoxymethyl-2-bromo-5-((2S,3R,4S,5R,6R)-3,4,5-triacetoxy-6-acetoxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran-4-yl ester 
• 30021-60-4 peracetylated methyl β-cellobioside 
• 13360-52-6 Cellobiose 
• 39483-51-7 ethyl 2,3,4-tri-O-benzyl-1-thio-β-D-glucopyranoside 
• 572-09-8 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide 
• 77068-17-8 3,6,2',3',4',6'-hexa-O-acetyl-2-O-(trichloroacetyl)-β-cellobiosyl chloride 
• 4753-07-5 2,3,6,2',3',4',6'-hepta-O-acetyl-α-D-maltosyl bromide 
• 4753-07-5 α-hepta-O-acetylmaltosyl bromide 

Downstream Products

• 74895-02-6 methyl 2,3,6-tri-O-acetyl-4-O-(2,3-di-O-acetyl-4,6-O-benzylidene-β-D-glucopyranosyl)-β-D-glucopyranoside 
• 1213789-33-3 C₄₃H₄₃B₅O₁₃ 
• 1213789-34-4 C₉₂H₈₉B₁₁O₂₆ 
• 1213789-32-2 methyl-4',6'-O-phenylboronate-β-D-cellobioside 
• 50-99-7 D-glucose 
• 69848-25-5 methyl-6,6'-di-O-tosyl-β-cellobioside 
• 1294447-11-2 methyl 2,3-di-O-acetyl-4,6-O-benzylidene-β-D-galactopyranosyl-(1→4)-2,3,6-tri-O-acetyl-β-D-glucopyranoside 
• 1272439-38-9 methyl 4-O-(2-O-acetyl-3-O-benzyl-4,6-O-benzylidene-α-D-glucopyranosyl)-2,3-di-O-acetyl-6-O-benzyl-α-D-glucopyranoside 
• 1272439-31-2 methyl 4-O-(3-O-benzyl-4,6-O-benzylidene-α-D-glucopyranosyl)-6-O-benzyl-α-D-glucopyranoside 
• 84094-20-2 methyl 4-O-(4,6-O-benzylidene-β-D-allopyranosyl)-β-D-allopyranoside 
• 84094-19-9 methyl 2,3,6-tri-O-acetyl-4-O-(2,3-di-O-acetyl-4,6-O-benzylidene-β-D-allopyranosyl)-β-D-allopyranoside 
• 84094-18-8 methyl 2,6-di-O-benzoyl-4-O-<3-O-benzoyl-4,6-O-benzylidene-2-O-(methylsulfonyl)-β-D-allopyranosyl>-2-O-(methylsulfonyl)-β-D-allopyranoside 
• 84094-16-6 methyl 4-O-<4,6-O-benzylidene-2,3-di-O-(methylsulfonyl)-β-D-glucopyranosyl>-2,3,6-tri-O-(methylsulfonyl)-β-D-glucopyranoside 
• 84093-87-8 methyl 2,3-di-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-6-O-p-tolylsulfonyl-β-D-glucopyranoside 

Relevant articles and documents

Characterization of a cellobiose phosphorylase from a hyperthermophilic eubacterium, Thermotoga maritima MSB8

The cepA putative gene encoding a cellobiose phosphorylase of Thermotoga maritima MSB8 was cloned, expressed in Escherichia coli BL21-codonplus-RIL and characterized in detail. The maximal enzyme activity was observed at pH 6.2 and 80°C. The energy of activation was 74 kJ/mol. The enzyme was stable for 30 min at 70°C in the pH range of 6-8. The enzyme phosphorolyzed cellobiose in an random-ordered bi bi mechanism with the random binding of cellobiose and phosphate followed by the ordered release of D-glucose and α-D-glucose-1- phosphate. The Km for cellobiose and phosphate were 0.29 and 0.15 mM respectively, and the kcat was 5.4 s-1. In the synthetic reaction, D-glucose, D-mannose, 2-deoxy-D-glucose, D-glucosamine, D-xylose, and 6-deoxy-D-glucose were found to act as glucosyl acceptors. Methyl-β-D- glucoside also acted as a substrate for the enzyme and is reported here for the first time as a substrate for cellobiose phosphorylases. D-Xylose had the highest (40 s-1) kcat followed by 6-deoxy-D-glucose (17 s-1) and 2-deoxy-D-glucose (16 s-1). The natural substrate, D-glucose with the kcat of 8.0 s-1 had the highest (1.1 × 104 M-1 s-1) k cat/Km compared with other glucosyl acceptors. D-Glucose, a substrate of cellobiose phosphorylase, acted as a competitive inhibitor of the other substrate, α-D-glucose-1-phosphate, at higher concentrations.

COMPOUNDS FOR TREATING AND PREVENTING NET ASSOCIATED COMPLICATIONS

The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of NETs in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating NET mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of NET mediated ailments. For example, the present invention relates to methods and uses of β-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.Na), in the therapy of a range of NET mediated ailments in subjects.

COMPOUNDS FOR TREATING AND PREVENTING EXTRACELLULAR HISTONE MEDIATED PATHOLOGIES

The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of extracellular histones in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating extracellular histone mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of extracellular histone mediated ailments. For example, the present invention relates to methods and uses of β-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.Na), in the therapy of a range of extracellular histone mediated ailments in subjects.

Completely β-selective glycosylation using 3,6- O-(o-xylylene)-bridged axial-rich glucosyl fluoride

A completely β-selective glycosylation that does not rely on neighboring group participation is described. The novelty of this work is the design of the glycosyl donor locked into the axial-rich form by the o-xylylene bridge between the 3-O and 6-O of d-glucopyranose. The synthesized 2,4-di-O-benzyl-3,6-O-(o-xylyene)glucopyranosyl fluoride could efficiently react with various alcohols in a SnCl2-AgB(C6F 5)4 catalytic system. The mechanism composed of the glycosylation and isomerization cycles was revealed through comparative experiments using acidic and basic molecular sieves. The achieved perfect stereocontrol is attributed to the synergy of the axial-rich conformation and convergent isomerization caused by HB(C6F5)4 generated in situ.